News

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming ...
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...
PipelineReview.com18h
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
OSAKA, Japan & BOSTON, MA, USA I June 23, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and ...
Science Daily12h
COVID-19 protein triggers immune attacks on healthy cells — but a common drug can stop it
Scientists have uncovered a stealthy tactic used by the SARS-CoV-2 virus: one of its proteins can leap from infected cells to ...
Oncolytic virus immunotherapy shows promise in HR+/HER2- breast cancer trial
The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...
BioPharma Dive4h
FDA investigating Elevidys safety; Nektar shares spike on eczema data
The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...
Sickle Cell Disease News14h
BEAM-101 shows sustained benefits as treatment for sickle cell
BEAM-101, a treatment for sickle cell disease, showed sustained efficacy and safety over one year in the BEACON Phase 1/2 ...